[go: up one dir, main page]

AR035001A1 - Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento - Google Patents

Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento

Info

Publication number
AR035001A1
AR035001A1 ARP990104054A ARP990104054A AR035001A1 AR 035001 A1 AR035001 A1 AR 035001A1 AR P990104054 A ARP990104054 A AR P990104054A AR P990104054 A ARP990104054 A AR P990104054A AR 035001 A1 AR035001 A1 AR 035001A1
Authority
AR
Argentina
Prior art keywords
lipase inhibitor
prepare
pharmaceutical compositions
gastrointestinal lipase
compounds
Prior art date
Application number
ARP990104054A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR035001A1 publication Critical patent/AR035001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Composiciones farmacéuticas de administración oral que contienen un inhibidor de lipasa gastrointestinal, uno (o más) aditivo(s) del grupo que consiste en espesantes y emulsionantes de baja digestibilidad, poca fermentabilidad, hidrófilos y/o hidrocoloides de grado alimenticio, y excipientes auxiliares; el comprimido masticable que lo comprende y el uso de uno (o más) compuesto(s) del grupo consistente en espesantes y emulsionante de baja digestibilidad, poca fermentabilidad, hidrófilos y/o hidrocoloides de grado alimenticio, que es para preparar un medicamento para el tratamiento o prevención del síndrome de pérdidas anales de aceite que se producen ocasionalmente tras la administración de un inhibidor de lipasa gastrointestinal, tal como orlistat, o tras la ingestión de alimentos que contienen grasas o aceites poco absorbibles o no absorbibles o sustitutos de grasas aceitosas indigeribles.
ARP990104054A 1998-08-14 1999-08-12 Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento AR035001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98115311 1998-08-14
EP99109516 1999-05-12

Publications (1)

Publication Number Publication Date
AR035001A1 true AR035001A1 (es) 2004-04-14

Family

ID=26149537

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104054A AR035001A1 (es) 1998-08-14 1999-08-12 Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento

Country Status (19)

Country Link
US (1) US6358522B1 (es)
EP (1) EP1105122B1 (es)
JP (1) JP3774118B2 (es)
KR (1) KR20010079635A (es)
CN (1) CN1170534C (es)
AR (1) AR035001A1 (es)
AT (1) ATE293970T1 (es)
AU (1) AU761351B2 (es)
BR (1) BR9912980B1 (es)
CA (1) CA2340056C (es)
CO (1) CO5130009A1 (es)
DE (1) DE69924999T2 (es)
DK (1) DK1105122T3 (es)
ES (1) ES2242413T3 (es)
MA (1) MA26671A1 (es)
PE (1) PE20000953A1 (es)
PT (1) PT1105122E (es)
TR (1) TR200100471T2 (es)
WO (1) WO2000009122A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
CA2342625A1 (en) 1998-09-08 2000-03-16 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
MXPA02012583A (es) * 2000-06-27 2003-04-10 Hoffmann La Roche Metodo para preparacion de una composicion.
ATE293477T1 (de) * 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
JP4265911B2 (ja) * 2000-07-28 2009-05-20 エフ．ホフマン−ラ ロシュ アーゲー 新規医薬組成物
DE60133470T2 (de) 2000-08-09 2009-05-07 F. Hoffmann-La Roche Ag Lipase inhibitoren zur behandlung von dyspepsia
JP4047723B2 (ja) 2000-10-16 2008-02-13 エフ．ホフマン−ラ ロシュ アーゲー インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
US6610685B2 (en) 2000-12-27 2003-08-26 Hoffmann-La Roche Inc. Fused indole derivatives
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2002338896B2 (en) 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
CN100383124C (zh) 2002-02-04 2008-04-23 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的喹啉衍生物
PL372463A1 (en) 2002-02-28 2005-07-25 F.Hoffmann-La Roche Ag Thiazole derivatives as npy receptor antagonists
CN1325050C (zh) 2002-04-26 2007-07-11 霍夫曼-拉罗奇有限公司 包含脂肪酶抑制剂和葡甘露聚糖的药物组合物
CN1665791A (zh) 2002-07-05 2005-09-07 霍夫曼-拉罗奇有限公司 喹唑啉衍生物
RU2324685C2 (ru) 2002-08-07 2008-05-20 Ф.Хоффманн-Ля Рош Аг Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
PL375878A1 (en) 2002-09-12 2005-12-12 F.Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
BR0316556A (pt) 2002-11-25 2005-10-04 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende esse composto, sua utilização e método para o tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas ppar(alfa) e/ou ppary
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
KR20060037435A (ko) 2003-08-12 2006-05-03 에프. 호프만-라 로슈 아게 2-아미노-5-벤조일싸이아졸 ｎｐｙ 길항물질
DE602004019939D1 (de) 2003-08-12 2009-04-23 Hoffmann La Roche Thiazolderivate als npy-antagonisten
CA2609634C (en) 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
US20090208584A1 (en) 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
EP1945635B1 (en) 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
BRPI0619268A2 (pt) 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
RU2412182C2 (ru) 2005-11-30 2011-02-20 Ф.Хоффманн-Ля Рош Аг Производные 1,1-диоксотиоморфолинилиндолилметанона для применения в качестве модуляторов гистамина 3 (н3)
CA2630270A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
CA2631128A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
DE602006010738D1 (de) 2005-12-15 2010-01-07 Hoffmann La Roche Pyrroloä2,3-cüpyridinderivate
WO2007068641A1 (en) 2005-12-16 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo [2 , 3-b] pyridine derivatives as h3 receptor modulators
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2008014532A (es) 2006-05-30 2008-11-27 Hoffmann La Roche Derivados de piperidinil pirimidinas.
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
US7862688B2 (en) * 2007-05-16 2011-01-04 Buckman Laboratories International, Inc. Methods to control organic contaminants in fibers
WO2009013195A1 (en) 2007-07-25 2009-01-29 F. Hoffmann-La Roche Ag Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
BR112018075415A2 (pt) * 2016-06-17 2019-03-12 The Procter & Gamble Company composição mastigável macia compreendendo plantago
CN112220831A (zh) * 2020-08-07 2021-01-15 天津盛实百草中药科技有限公司 圆苞车前子壳粉在缓解奥利司他副作用中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JPH09252746A (ja) * 1996-03-22 1997-09-30 Nippon Kankyo Yakuhin Kk 栄養補助食品
JP4202439B2 (ja) * 1996-10-01 2008-12-24 江崎グリコ株式会社 フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions

Also Published As

Publication number Publication date
CO5130009A1 (es) 2002-02-27
US6358522B1 (en) 2002-03-19
MA26671A1 (fr) 2004-12-20
DE69924999D1 (de) 2005-06-02
DE69924999T2 (de) 2006-05-04
CN1170534C (zh) 2004-10-13
CN1312713A (zh) 2001-09-12
WO2000009122A1 (en) 2000-02-24
JP3774118B2 (ja) 2006-05-10
BR9912980A (pt) 2001-05-08
PT1105122E (pt) 2005-08-31
PE20000953A1 (es) 2000-09-26
AU5418599A (en) 2000-03-06
ATE293970T1 (de) 2005-05-15
ES2242413T3 (es) 2005-11-01
TR200100471T2 (tr) 2001-07-23
CA2340056C (en) 2007-01-09
JP2002522491A (ja) 2002-07-23
BR9912980B1 (pt) 2013-10-22
CA2340056A1 (en) 2000-02-24
EP1105122A1 (en) 2001-06-13
DK1105122T3 (da) 2005-08-08
EP1105122B1 (en) 2005-04-27
KR20010079635A (ko) 2001-08-22
AU761351B2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
AR035001A1 (es) Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento
US8853269B2 (en) Composition and method for treating infections and promoting intestinal health
DE69815677D1 (de) Orale zubereitung zur prophylaktischen/therapeutischen behandlung von helicobactor sp. infektionen
AR029615A1 (es) Una formulacion farmaceutica para la administracion oral
BR9908121A (pt) Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção
BR9611802A (pt) Composições farmacêuticas
AR035652A1 (es) Una composicion nutricional, util para combatir la infeccion en el tracto gastrointestinal causada por organismos tipo helicobacter, el uso de dicha composicion para la preparacion de medicamentos, o productos alimenticios y el procedimiento para preparar dicha composicion
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CN101835464A (zh) 抗疟疾药物组合物
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
KR970061244A (ko) 치매 치료용 약학 조성물
PT1221867E (pt) Composicao nutritivo compreendendo um precursor da anandamida
BR0109012A (pt) Composição farmacêutica, forma de dosagem unitária, solução oral, método para o tratamento da dor, e, método para o tratamento de inflamações
RU2004134573A (ru) Фармацевтическая композиция, включающая ингибитор липазы и глюкоманнан
KR970705988A (ko) 연골 조직의 이상에 기인하는 질환의 예방 또는 치료제(Preventive or remedy for diseases caused by abnormalities in cartilage tissues)
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
JP5795760B2 (ja) ジヒドロアルテミシニンを含む舌下スプレー用製剤
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
RU2006131758A (ru) Композиция для предупреждения простуды
AU763995B2 (en) Treatment of dyspepsia
BR0112830A (pt) Medicamento destinado especialmente a combater as disfunções sexuais
RU2010125505A (ru) Фармацевтический набор из эмульсии типа "масло в воде" и твердой композиции
AR012702A1 (es) Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente
KR980700083A (ko) 골다공증 치료 주기용 키트(KIT for Osteoporosis Treatment Cycle)

Legal Events

Date Code Title Description
FG Grant, registration
FC Refusal